In patients with high and low Axl expression in tumors, the 1‐, 3‐, 5‐ and 7‐year HCC recurrence rates were 19.3%, 58.6%, 77.9% and 85.9% and 3.0%, 17.2%, 37.1% and 53.7%, respectively (Figure 1A). This evidence concerns the gene AXL and hepatocellular carcinoma.